Joon Lee
Stock Analyst at Truist Securities
(4.62)
# 159
Out of 4,829 analysts
119
Total ratings
54.21%
Success rate
36.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joon Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Reiterates: Buy | $95 → $75 | $27.55 | +172.23% | 8 | Apr 28, 2025 | |
| ARVN Arvinas | Maintains: Buy | $65 → $21 | $6.61 | +217.70% | 6 | Apr 9, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $76 → $150 | $70.23 | +113.58% | 8 | Mar 31, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $90 → $50 | $8.12 | +515.76% | 4 | Mar 4, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $175 → $85 | $38.35 | +121.64% | 5 | Mar 3, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $190 → $200 | $107.76 | +85.60% | 5 | Feb 19, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $100 → $120 | $35.62 | +236.89% | 5 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $460 → $520 | $424.99 | +22.36% | 3 | Feb 11, 2025 | |
| LRMR Larimar Therapeutics | Initiates: Buy | $18 | $2.12 | +749.06% | 1 | Jan 29, 2025 | |
| ARGX argenx SE | Reiterates: Buy | $660 → $700 | $549.27 | +27.44% | 12 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $44 → $57 | $63.32 | -9.98% | 6 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.76 | +479.71% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $36 | $6.59 | +446.70% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $36 | $23.37 | +54.04% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $1.45 | +451.72% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $13 → $8 | $6.57 | +21.77% | 11 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $17 | $11.66 | +45.80% | 7 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $90 | $58.86 | +52.91% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $40 | $2.81 | +1,323.49% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $97.78 | +104.54% | 2 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.13 | +134.74% | 7 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.17 | +467.82% | 1 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $280 | $3.14 | +8,831.42% | 1 | Oct 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $27 → $34 | $19.62 | +73.29% | 1 | Mar 16, 2021 |
Viking Therapeutics
Apr 28, 2025
Reiterates: Buy
Price Target: $95 → $75
Current: $27.55
Upside: +172.23%
Arvinas
Apr 9, 2025
Maintains: Buy
Price Target: $65 → $21
Current: $6.61
Upside: +217.70%
Corcept Therapeutics
Mar 31, 2025
Maintains: Buy
Price Target: $76 → $150
Current: $70.23
Upside: +113.58%
Intellia Therapeutics
Mar 4, 2025
Maintains: Buy
Price Target: $90 → $50
Current: $8.12
Upside: +515.76%
Praxis Precision Medicines
Mar 3, 2025
Maintains: Buy
Price Target: $175 → $85
Current: $38.35
Upside: +121.64%
Axsome Therapeutics
Feb 19, 2025
Maintains: Buy
Price Target: $190 → $200
Current: $107.76
Upside: +85.60%
CRISPR Therapeutics AG
Feb 12, 2025
Maintains: Buy
Price Target: $100 → $120
Current: $35.62
Upside: +236.89%
Vertex Pharmaceuticals
Feb 11, 2025
Maintains: Buy
Price Target: $460 → $520
Current: $424.99
Upside: +22.36%
Larimar Therapeutics
Jan 29, 2025
Initiates: Buy
Price Target: $18
Current: $2.12
Upside: +749.06%
argenx SE
Jan 14, 2025
Reiterates: Buy
Price Target: $660 → $700
Current: $549.27
Upside: +27.44%
Jan 8, 2025
Reiterates: Buy
Price Target: $44 → $57
Current: $63.32
Upside: -9.98%
Jan 8, 2025
Initiates: Buy
Price Target: $16
Current: $2.76
Upside: +479.71%
Nov 12, 2024
Maintains: Buy
Price Target: $17 → $36
Current: $6.59
Upside: +446.70%
Nov 11, 2024
Maintains: Buy
Price Target: $30 → $36
Current: $23.37
Upside: +54.04%
Nov 5, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $1.45
Upside: +451.72%
Oct 30, 2024
Maintains: Hold
Price Target: $13 → $8
Current: $6.57
Upside: +21.77%
Oct 22, 2024
Maintains: Buy
Price Target: $12 → $17
Current: $11.66
Upside: +45.80%
Sep 17, 2024
Maintains: Buy
Price Target: $118 → $90
Current: $58.86
Upside: +52.91%
Aug 14, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $2.81
Upside: +1,323.49%
Mar 20, 2024
Reiterates: Buy
Price Target: $200
Current: $97.78
Upside: +104.54%
Sep 20, 2023
Maintains: Buy
Price Target: $6 → $5
Current: $2.13
Upside: +134.74%
May 10, 2023
Initiates: Buy
Price Target: $18
Current: $3.17
Upside: +467.82%
Oct 20, 2021
Initiates: Buy
Price Target: $280
Current: $3.14
Upside: +8,831.42%
Mar 16, 2021
Upgrades: Buy
Price Target: $27 → $34
Current: $19.62
Upside: +73.29%